Acro Biomedical Co., Ltd. (ACBM) stock
ACBMOTCServices-Amusement & Recreation ServicesFiscal year ends December 31
$0.03+0.00 (0.00%)
Close on Oct 19, 2026Market cap $1.56MP/E –Yield –
Acro Biomedical r&d expenses
Research and development expenses are spending on new products and technology.
Acro Biomedical's R&D Expenses for the twelve months ending Dec 31, 2024 was $0, down 100.0% year over year. For fiscal 2024 it was $0, down 100.0% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | -100.0% |
| FY2023 | Dec 31, 2023 | $4.79M | -52.4% |
| FY2022 | Dec 31, 2022 | $10.08M | +90.7% |
| FY2021 | Dec 31, 2021 | $5.29M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $0 | -100.0% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $396.55K | -84.3% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $1.88M | -25.5% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $2.52M | 0.0% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $2.52M | 0.0% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $2.52M | +18.7% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $2.52M | +292.7% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $2.52M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $2.52M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $2.12M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $641.73K | – |
See a number that looks wrong?